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Abstract  
Objectives: There are various obstacles in the eradication of Helicobacter.pylori (H. pylori) 
infections, including low antibiotic levels and poor accessibility of the drug at the site of the 
infection. This study describes the preparation and characterisation of novel floating-
mucoadhesive alginate beads loaded with clarithromycin (CMN) for delivery to the gastric 
mucosa to improve the eradication of this micro-organism.  
Methods:  Calcium alginate beads were prepared by ionotropic gelation. The formulation 
was modified through addition of oil and coating with chitosan in order to improve floating, 
mucoadhesion and modify drug release.  
Key findings: SEM confirmed the sphericity of the beads with X-ray microtomography 
(XµMT) showing the 3D structure of the beads with the layered internal structure of the bead 
and the even distribution of the drug within the bead. This formulation combined two gastro-
retentive strategies and these formulations produced excellent in vitro floating, mucoadhesive 
and drug release characteristics.  Enhanced stability of the beads in phosphate buffer raises a 
potential for the modified formulations to be targeted to regions of higher pH within the 
gastrointestinal tract with a higher pH. Drug release from these beads was sustained through 
an unstirred mucin layer simulating in vivo conditions under which the H. pylori resides in 
the gastric mucosa. 
Conclusions:  This novel formulation will ensure retention for a longer period in the stomach 
than conventional formulations and control drug release, ensuring high local drug 
concentrations, leading to improved eradication of the bacteria. 
 
Introduction 
The development of conditions such as chronic active gastritis, peptic ulcer disease, gastric 
mucosal-associated lymphoid tissue lymphoma and gastric carcinoma has been linked to H. 
pylori infection [1-3]. Infection with this Gram-negative micro-aerophilic bacterium is silent 
and a percentage of the infected population will develop conditions such as chronic gastritis, 
peptic and duodenal ulcers [4]. About half a million new cases/year of gastric cancer, about 
55 % of the total cases worldwide, have been linked to H. pylori and it has been predicted to 
be one of the top ten leading causes of death worldwide by 2020 [5, 6].  H. pylori infection is 
considerably higher in developing countries  (80 – 90 %), than in developed countries (10 – 
50 % of the total population) [7]. H. pylori attach to the gastric epithelial cells causing 
progressive injury to the gastric mucosa and its function [8, 9]. H. pylori is sensitive to many 
antibiotics in vitro; however no single agent is effective alone in vivo [10], therefore, a 
combination therapy is required to effectively eradicate the bacterium. Infections are difficult 
to eradicate because the bacterium resides below the gastric mucus adherent to the gastric 
epithelium; therefore, access of drugs to this particular site is limited. In addition, the bacteria 
can acquire resistance to the commonly used antimicrobial drugs [11], therefore a 
combination of two antibiotics including CMN, amoxicillin and metronidazole with a gastric 
acid inhibitor remains the first line therapy regimen for the eradication of H.pylori [12, 13]. 
However, the persistent rise in resistance of this bacterium to these antibiotics; the hostile 
environment of the stomach which reduces antibiotic bioavailability at the site of action [14] 
and the formation of biofilms by H.pylori on the gastric mucosa epithelium can cause 
treatment failures [15]. Another major problem is limited gastric residence of conventional 
antibiotic formulations (0.5 - 2 h), which even if designed to ensure release of drug over a 
longer period of time may not be retained in the stomach for that long.  This has encouraged 
research into producing alternatives to the commonly used therapies [16]. Gastroretentive 
dosage forms (GRDFs) may prolong the residence time of dosage forms in the stomach [17] 
and must be strong enough to withstand peristaltic waves of the stomach and be easily 
removed from the stomach upon drug release [18]. GRDFs such as floating systems have a 
bulk density lower than that of gastric fluid and therefore remain buoyant on stomach 
contents without affecting gastric emptying for a prolonged time [19]. Mucoadhesive systems 
can provide an intimate contact between the delivery system and the underlying target 
mucosal surface, thereby improving the bioavailability [20] and therapeutic performance of 
the drug [21] by plugging and sealing the mucosal cell in the gastrointestinal (GI) tract [22] 
whilst controlling drug release. The use of a combined floating and mucoadhesive drug 
delivery system will explore any synergy between the mechanisms, thereby overcoming the 
shortcomings of the individual system [23]. This approach may extend the duration of 
retention in the stomach [24] and this, in addition to a sustained drug release profile, may lead 
to an enhancement in activity and reduced dosing frequencies [25]. In this study, sodium 
alginate (SAL), a natural hydrophilic polymer was used to prepare novel CMN-loaded 
calcium alginate beads as a potential gastroretentive floating-mucoadhesive drug delivery 
device. The SAL beads were modified to improve the floating and mucoadhesive properties 
by including olive oil (an oil with reported anti-H.pylori activity ([26, 27] and inclusion of 
with chitosan (a mucoadhesive polymer [28] forming a polyelectrolyte complex membrane 
respectively, both of which control CMN drug release.  This formulation method has been 
explored separately with either modification with oil or polymer coating but not as a 
combination of both in the delivery of CMN from alginate beads. These formulations should 
have the advantage of supplying high local concentrations of CMN into the gastric mucosa, 
where H. pylori is resident, leading to more effective targeting of this bacteria and a reduction 
in dose [29] thereby, reducing the risk of drug resistance.  
 
 
Materials and Methods 
Materials  
SAL, chitosan, olive oil, calcium chloride dihydrate (CaCl2.2H2O), Mucin Type (III) and 
CMN were obtained from Sigma Aldrich (UK). 
HPLC assay  
 
HPLC was performed on a Shimadzu system equipped with a SPD-20 AV Prominence 
UV/VIS detector, an LC 20 AT pump, and SIL-20A Prominence auto-sampler. Data 
acquisition was carried out on a LC solution software integrator with separation performed 
using a SphereClone 5μm ODS (2) column (150 x 4.6 μm) (Phenomenex). Mobile phase was  
KH2PO4 ( 50 mM ): ACN, pH 4.6 (50:50 v/v) containing 5 mM 1-Octanesulphonic acid (1-
OCTS) [30], at a flow rate of 1.5 ml/min determined at 50 °C with an  injection volume of 50 
μl and a  run time of 5 minutes. 
 
 
Preformulation studies  
Stability of CMN and determination of degradation rate constant  
Solubility was assessed by adding excess CMN in buffers (pH= 1.2 - 8) and  the solution was 
agitated continuously for 1 h. Stability of CMN was assessed by dispersing CMN (50 mg) in 
100 ml buffers (pH = 1.2 - 7) maintained at 37 ± 1 °C and stirred at 100 rpm. Sampling was 
done at different time intervals after adjusting the pH to 5.0 to prevent further degradation 
and analysed. The half life (t1/2) of CMN was determined from the pseudo first order 
degradation rate constant (k). 
 
  
 
Preparation and optimisation of beads 
SAL suspension (10 g) was extruded drop-wise into CaCl2.  The beads formed were 
collected, washed, frozen in liquid N2 and freeze dried for 24 h. Optimisation for the ideal 
concentrations of SAL, CaCl2 and curing times required for formation of discrete spherical 
beads in our laboratory have been detailed in a previous article [31]. Drug loaded beads were 
prepared by dispersing CMN evenly in the SAL solution before extrusion into the CaCl2 
solution (Table 1).  
 
Preparation of modified beads 
Olive oil was added to 10 g of SAL solution and homogenised for 10 min to form a stable 
emulsion. CMN was added to the emulsion and the beads prepared as detailed in the previous 
section. Some of the beads were coated with chitosan solution to enhance the mucoadhesion 
and control the drug release (Table 1). Chitosan was dissolved in 1 % v/v glacial acetic acid 
and the beads were immersed in the coating medium for 30 min. The beads were washed, 
filtered and dried as before.  
 
Characterisation of beads 
Study of morphology and physical characteristics of alginate beads 
Bead sizes (n = 50) were measured with an electronic digital calliper [32]. The three 
dimensional structure, surface and internal pore structure of the beads were obtained using X-
ray microtomography (XµMT) (Nikon XTH225 X-Ray Microtomography) and scanning 
electron microscopy (SEM) (Stereoscan 90 Scanning Electron Microscope (Cambridge, UK). 
Density measurements and porosity 
 Dry beads were filled to the mark of a 10 ml volumetric cylinder (W1) which was weighed 
(W2). The bulk density ( Pb) of the beads was calculated using:  
                                                                                [33],   
 
where, W2 is the weight of the beads and the cylinder , and W1 is the weight of the cylinder  
only. The true densities (Pt) of the beads were determined using a (Quantachrome 
multipycnometer (Model MVP-D160-E)) with a 5 cm3 micro sample cup. The porosity P of 
the beads was determined using the formula  
 
                                                      P =         [34, 35] 
 
Drug loading and drug entrapment efficiency (DEE) 
Beads (100 mg) were digested in 100 ml PBS (phosphate buffered saline) under agitation at 
37 °C over 24 h, assayed and parameters calculated using the following equations.  
               ቀ   ቁ                                                                                  
                                                                                                                                       
     
Calcium content of beads  
Beads (100 mg) was dissolved in 10 ml concentrated HNO3 by heating at 50 °C. This 
solution was diluted and analysed for Ca2+ ion at 422.7 nm by flame Atomic absorption 
spectroscopy (Perkin Elmer AAnalyst 100). 
 
Loose surface crystals (LSC) 
Beads (100 mg) were agitated for 5 minutes in 100 ml PBS (pH 7.4) using a mechanical 
shaker and the leached drug was assayed using HPLC. The % LSC was calculated using the 
following equation: 
                                                                        
 
 Differential scanning calorimetry (DSC) 
Samples (5 - 10 mg) were held at 25 °C for 1 min and then heated from 25 °C to 300 °C at a 
rate of 10 °C / min under N2 atmosphere using a DSC-1 Mettler Toledo (Mettler-Toledo, 
Switzerland).  
 
Powder X-ray diffraction analysis (P-XRD) 
 
 Powdered samples were placed and levelled in a stainless steel holder and analysed using a 
Bruker D2 Phase diffractometer (Bruker, UK). The samples were scanned between 5 and 40 
of 2θ with a step size of 0.019° and a step time of 32.5 s. 
 
 
 FTIR 
 
Samples were scanned from 400 - 4000 cm-1 using a Thermo Nicolet 380 FTIR with 
Diamond ATR. The characteristic peaks of IR spectra were recorded.  
 
Zeta potential (Zp)  
Suspensions of the beads in 0.1N HCl (pH 2.0) and phosphate buffer (pH 6.8) were sonicated 
and analysed using Zetasizer Nano Z (Malvern Instruments Ltd., UK). Each sample was 
analysed six times to obtain an average value and a SD. 
 
Determination of in vitro buoyancy lag time and duration 
Beads (n = 50) were placed in 0.1N HCl (pH 2.0) containing 0.02 %w/v Tween 20 
maintained at 37 ± 1 °C and agitated at 100 rpm for 24 h using a USP Type II dissolution 
apparatus. The floating lag time and the duration of floating were recorded. 
 
Swelling studies 
Beads were immersed in 100 ml of 0.1N HCl (pH 2.0) or PBS (pH 7.4) and, at fixed time 
intervals; the beads were removed, dried and weighed. Dynamic weight change of the beads 
was calculated according to the formula: 
                                                                  
where,    Ws is the weight of the beads in the swollen state 
               Wi is the initial weight of the beads. 
 
In vitro drug release and release kinetics 
Drug release was studied from beads equivalent to 100 mg CMN using USP Type 1 
dissolution apparatus in 0.1N HCl (pH 2) or PBS (pH 7.4) agitated at 100 rpm and 
maintained at 37 ± 1 °C. Release kinetics was assessed using various kinetic models [36-40] 
and f2 analysis [41].  
 
Drug release in mucin suspension 
In vitro diffusion of encapsulated drug through a 3 % w/v mucin suspension at pH 2 and pH 
5, were carried out using vertical Franz diffusion cells. The receptor compartment contained 
30 ml buffer maintained at 37 ± 1 °C and agitated at 400 rpm. Dialysis membrane (cut off 
MW 14,000) was mounted between the donor and receiver cells with the mucin suspension 
representing an unstirred layer and 1 ml of receptor fluid was sampled and analysed. 
 
Ex vivo wash off mucoadhesion tests  
A 5 cm wide and 3 cm long piece of porcine gastric mucosa was mounted onto a Perspex 
mounting block and 30 beads were spread evenly on the tissue surface, and allowed to 
incubate for ~ 20 min. The block was positioned at an angle of 30 ° in a humidity chamber (ޓ 
90 % RH) and maintained at 37 ± 1 °C. Buffers at pH 2.0 (0.1 N HCl) and pH 7.4 (PBS) were 
circulated over the tissue at a rate of 1 ml/min for 8 h. Beads remaining on the tissue after 
each hour were counted and the percentage of the remaining microspheres was calculated 
using the formula: 
 
                                                          
 
 
where,  N0= number of beads applied initially and Ni = number of beads rinsed from the 
tissue. 
Storage stability of beads  
Beads were sealed in vials and stored at 4° C and room temperature (20 ºC) over a period of 
three months. The drug loading, Zp, mucoadhesion and in vitro release were determined at 
the end of days 30, 60 and 90. 
Statistical analysis 
 Data were expressed as mean ± SD (standard deviation). Student t tests and one way analysis 
of variance (ANOVA) were used to determine statistical significance. Probability values p > 
0.05. 
 
Results  
Preformulation studies 
HPLC assay 
CMN was detected at 210 nm with a retention time of ~ 2.5 min. The limit of detection 
(LOD) and limit of quantification (LOQ) were 1.85 ˃0.01 μg/ml and 5.63 ˃ 0.05 μg/ml, 
respectively. The intra-day and inter-day relative standard deviation (RSD) were < 5%. 
 
Solubility and stability profile of CMN  
 
Solubility and stability of CMN is pH dependent (Figure 1a and 1b) with the highest 
solubility (~ 17 mg/ml) and lowest stability observed at the lowest pH studied.  k values at pH 
1.2, 2.0, 3.0 and 5.0 were 1.45 ± 0.13 h-1; 0.45 ± 0.01 h-1 , 0.055 ± 0.007 h-1 and 0.0028 ± 
0.0003 h-1 respectively with CMN being more stable as pH increased and the t1/2 were 0.47 ± 
0.04 h, 1.53 ± 0.005 h, 12.65 ± 1.72 h and over 100 h respectively. These results correspond 
to results obtained by earlier studies [42]. 
 
Characterization of beads 
Beads were spherical as shown in Figure 2. XµMT was used to visualise the bead structure 
without any prior treatment (Figure 2 a-f) unlike SEM (Figure 2 g- i).  Diameter and bulk 
density increased with drug - polymer ratio (p < 0.05) (Table 2) with porosity > 75 %. The 
calcium content was reduced with an increase in drug content (p < 0.05). 
 
 
Drug loading and DEE 
 
DEE was > 80 % (Table 2), even at low drug-polymer ratios and this was due to the low 
solubility of CMN in 1% CaCl2 solution which was determined to 2.1 ± 0.82 mg/ml.  Olive 
oil  increased the DEE of  the beads by ~ 6 %  with coating having no effect on DEE. Drug 
loading had no effect on LSC,  which was reduced by at least 75 % following coating of the 
beads (Table 3). 
 
Buoyancy profile 
E1 - E4 samples (unmodified beads) floated initially with a lag time < 3 min, however  40-50 
% of the beads sank after the first hour. After 24 hours, only 15 - 45 % of the beads remained 
floating. Beads loaded with 10 %w/w oil retained bouyancy lag times were < 1 min (p < 
0.05) (Table 2).  
DSC  
 CMN showed a single endothermic peak with an average onset at  227.5 ± 0.32 °C  (n=3), 
which corresponds to its documented melting point. The physical mixture of CMN and SAL 
and drug loaded beads (both modified and unmodified beads) had similar endothermic peaks 
at 226.74 ± 0.78 °C (n = 3) and  226.56 ± 0.89 °C (n = 3) respectively (Figure 3).  
 
 
P-XRD   
P-XRD profiles of the beads showed characteristic peaks observed in CMN. However, there 
was a significant reduction in peak intensities in the drug loaded beads due to the 
encapsulation process (Figure 4).  
 
FT-IR 
Characteristic bands of E1 (blank beads) were at 3381.5 cm-1 representing the O-H band , 
1606.9  cm-1  and 1428.4 cm-1 representing the asymmetric band of the carboxylate , the band 
at 1032 cm-1 is given by the guluronic units [43], and 819.6 cm-1, identified in the literature as 
the combination of three possible vibrational modes (tCO+dCCO+dCCH) [44]. IR spectra of 
CMN showed the characteristic band of hydrogen bonds between –OH groups vibration at 
3479.5 cm-1 (Figure 5).  The characteristic band C=O vibration of the lactone group at 1732.9 
cm-1 and strong absorption band at 1692 cm-1 belonging to the carbonyl ketone peak for N-
CH3 stretching of aromatic ring at 1457.7 cm-1 (Figure 6). Drug loaded CMN beads (both 
modified and unmodified) showed similar peaks with reduced intensities. 
Swelling studies 
Swelling of E1 (blank) in HCl was about 350 % w/w and this was achieved after ~ 100 min. 
The presence of drug and modification of the beads led to a reduction in swelling (Figure 7a). 
In PBS, E1 exhibited maximal swelling of about 2500 % w/w, which was achieved between 
100 and 150 min. The beads subsequently started to disintegrate after this time leading to a 
reduction in weight (Figure 7b). Oil-modified beads both coated and uncoated showed 
maximal swelling of ~ 250 % with an increase in time for complete dissolution of the beads 
in PBS. The coated oil modified beads remained stable till the end of this study at 6 h.   
 
Zeta potential (Zp) 
 Zp increased positively and there was an inversion of Zp on inclusion of chitosan in the bead 
formulation (Figure 10a). This was observed at both pH levels; however, the degree of 
change was larger at pH 2.0 because at this pH, chitosan is highly positively charged. E1 
beads were negatively charged and this negative charge increased negatively with an increase 
in pH due to the presence of ionized carboxylic groups of the alginic acid   
 In vitro drug release 
Drug release was biphasic with an initial rapid release followed by a subsequent slower 
release. Drug release from E4 (10 % w/w CMN) was more sustained than E2 (1% w/w CMN) 
where release was rapid (p < 0.05) (Figure 8a). This is as a result of the drug content as beads 
with higher drug loading exhibited slower release rates.  Although the addition of oil did not 
impact the release rate (p > 0.05) (f2 = 62.7); coating with chitosan reduced the release rate (p 
< 0.05) (f2 = 30.1) (Figure 8b), however the molecular weight of chitosan used had little 
effect on drug release (f2 = 57.4). E2 – E6 (unmodified and oil modified) formulations fitted 
well to Higuchi kinetics (R2 ޓ 0.99), while the coated beads exhibited zero order kinetics (R2 
ޓ 0.99). This was followed closely by Higuchi kinetics (R2 ޓ 0.98). The release exponent, n ≤ 
0.45 indicates Fickian transport drug release mechanism (Table 4) with an initial rapid release 
followed by tailing over time.   
The release of CMN from these beads in PBS was rapid when compared with release in the 
acidic media (Figure 8c). After 2 h, the unmodified beads started to disintegrate and complete 
release was achieved after this time. However, in the coated oil-modified beads, drug release 
was more sustained and complete drug release was achieved at ~ 8 h with the beads 
completely dissolving at ~ 9 h. The release exponent on fitting to the Korsmeyer-Peppas 
model was 0.46 ≤ n < 0.53 also indicating non-Fickian diffusion.   
 
 
Drug release in mucin suspension 
Drug diffusion from beads through mucin solution was sustained over a period of 12 h at both 
pH levels. There was no burst release from the beads and release from E10 was reduced 
compared to E4. Drug fluxes were 1020.13 ± 30.12 µg cm-2 h-1 (saturated CMN solution);   
355 .3 ± 5.78 µg cm-2 h-1 (unmodified beads, E4) and 221.1 ± 9.43   µg cm-2 h-1 (coated oil 
modified bead, E10) at pH 2.0 (Figure 9a).  At pH 5.0, the fluxes were significantly reduced 
(p < 0.05) compared with those observed at pH 2.0 with flux of saturated solution being 
734.8 ± 46.31 µg cm-2 h-1 ;  198.7 ± 23.52   µg cm-2 h-1 (E4) and 87.8 ± 6.41  µg cm-2 h-1 
(E10) (Figure 9b). This change in flux is due to the differences in solubility of CMN at both 
pH levels.    
 Mucoadhesion tests  
In acidic media, ޓ 50 % beads detached from the porcine mucosa after the first hour and the 
presence of drug reduced the mucoadhesion in unmodified beads. However, more than 80 % 
beads remained attached within the same time interval for the coated oil modified beads and 
up till the end of the study at 8 h.  The adhered beads were between 13.3 ± 6.6 and 43.3 ± 9.9 
at pH 7.4 (Figure 10b) after 8 h. 
 
Storage stability  
After 3 months of storage at both 4 °C and 20 °C, there were  no significant differences in the 
DEE, Zp, buoyancy, mucoadhesion and  drug release. f2 values for comparison of 
formulations at the beginning and end of the stability study were all  ޓ 50, indicating 
similarity of the profiles.  
 
Discussion  
Stability of CMN at different buffer pHs was assessed due to its instability in acidic pH [45, 
46] and without this, drug release would be underestimated [47]. Also, due to the fact that 
CMN is used in combination with other stomach acid reducing drugs, it was important to 
assess its stability.  XµMT and SEM images showed the macroporous internal structure of the 
hydrogel, with concentric layers with voids between the layers (Figure 2). The contour 
structure is associated with the cross-linking direction of the external gelation process from 
the surface to the core of the beads. The pores occur in areas of former ice crystals and are 
unique to freeze dried alginate beads and this aids buoyancy [48] producing beads with a bulk 
density less than 1 g/cm3. The homogenous distribution of CMN in the beads was observed in 
Figure 2e, which also demonstrates the crystalline nature of the drug in the beads. This is an 
important property of drug loaded alginate beads and this even distribution is attributed to the 
fine particle size of CMN and its tendency not to sediment in the polymer solution. This is in 
contrast to the observation of the uneven distribution of drug in beads observed by other 
researchers [49]. Drug rendered the beads less porous with the CMN occupying the 
interstitial spaces between the layers. Also, oil acts as a hydrophobic floating aid and as a 
dispersed phase to prepare a stable emulsion and create multiple tiny pockets in the matrix to 
enhance its buoyancy (Figure 2c, 2f and 2i) and Table 2. 100 % buoyancy of the beads was 
achieved with the addition of 10 % w/w olive oil with a floating lag time of ޒ 1 min 
compared with the lag times of unmodified beads which were ~ 3 min. The presence of Olive 
oil may provide a synergistic effect against the bacteria due to its reported anti H. pylori 
activity. Solid state characterization of the oil modified/ coated oil modified beads (E6 /E10) 
by DSC, P-XRD and FTIR showed no significant change in the scans indicating crystalline 
nature and stability of the drug in the formulation. This further confirms the presence of the 
crystalline drug observed in XµMT images (Figure 2e).  In acidic media, CMN release from 
the unmodified beads was biphasic, fast (due to the solubility of CMN at this pH and the 
presence of dispersed drug) and was complete within 6 h with drug release rate reducing with 
an increase in drug-polymer ratio (p ޒ 0.05). Modification of the beads with oil and further 
coating led a significant reduction in drug release rate extending drug release from an initial 6 
h (unmodified beads) to ~ 12 h (Figure 8). When the unmodified calcium alginate beads are 
exposed to media with a pH > 4.0, Ca2+ ions are displaced from the alginate network and the 
carboxyl residues are protonated to form alginic acid [50, 51] due to an ion exchange with 
displacement of Ca ion by Na from PBS, leading to chain relaxation and gel swelling.  The 
formation of calcium phosphate renders the calcium alginate structure loose and soluble [52]. 
However, for the oil modified and coated oil modified beads, this ion exchange was affected 
with the maximum swelling being significantly reduced and complete dissolution of the 
unmodified; oil modified and coated oil modified beads being ~ 240 min, ~ 360 min and ~ 
600 min respectively. CMN release in PBS was still overall faster than that observed in acidic 
media due to the progressive increase in pore volume in the swollen beads. Higuchi kinetics 
has previously been reported to describe drug release from alginate beads [47]. Coating of the 
beads reduced the porosity at the bead surface leading to a more sustained drug and by 
varying the molecular weight of the chitosan used; there was a further reduction in the drug 
release. 
The negative charge of alginate beads allows ionic interaction with positively charged 
chitosan and the Zp inversion confirmed successful incorporation of chitosan within the 
formulation. The ex-vivo mucoadhesion tests demonstrated improved mucoadhesive 
properties of the oil modified formulations compared with the lower mucoadhesion exhibited 
with SAL formulations. This suggests the likely modification of the bead surface on addition 
of chitosan. Drug transport rate through mucus can be an important determinant of the 
efficacy of a formulation. Mucus is the primary barrier with which drugs must interact and 
diffuse through for drugs to be absorbed. The mucus layer of the stomach and the intestine 
are reported to be 50 - 600 µm and 15 - 450 µm respectively [53-55]. Interspecies variations 
in mucus thickness limit the suitability of common laboratory animals for in vivo studies [56]. 
Drug release through mucin suspension demonstrated there was a sustained and adequate 
release of drug from the beads and the presence of chitosan on the surface of the beads did 
not hinder drug release in the presence of mucin. This method represents a more realistic in 
vitro drug release model as it better represents the in vivo environment. There was ~ 40 % 
reduction in flux with coated oil modified beads (E10) versus unmodified beads (E4) as a 
result of reduction of surface associated drug (no burst release); the interaction of mucin with 
the chitosan surface of the bead, thereby making the bead surface less available for outward 
drug diffusion and the presence of oil. Therefore this formulation will release its drug content 
when adhered to the stomach mucosa and have the potential to penetrate through the mucus 
where the H. pylori is resident.  
 
The decreased mucoadhesion of the beads in PBS may be as  result of the loss of the calcium 
ion from the beads [57, 58] and reduced interaction between chitosan and the mucus at this 
pH.  Mucoadhesion occur with an initial wetting process causing an intimate contact between 
the mucus and the swelling mucoadhesive polymer. The polymer strands relax, followed by 
penetration of the polymer chains into the mucus network and finally the formation of 
secondary chemical bonds. A combination of the results from  the ex vivo wash-off test and 
the buoyancy tests indicate that the coated oil modified beads containing CMN have a 
potential for mucoadhesion to the stomach mucosa and floating in the stomach. Storage of 
the beads at both 4 °C and 20 °C over 90 days did not show any significant change in the 
physical characteristics such as the color and texture. In addition, there was no significant 
difference in all DEE, Zp, buoyancy, mucoadhesion and drug release therefore, the 
formulations were stable and could be stored at these temperatures without any requirement  
for special storage conditions.  
 
Conclusion 
Emulsion gelation method was successfully used to produce floating CMN beads. The beads 
produced were spherical as confirmed by SEM and XµMT with over 80 % DEE. Buoyancy 
was enhanced by modification with oil and by coating the beads with chitosan a 
mucoadhesive surface layer was added. The coated beads adhered to the porcine gastric 
mucosa and sustained drug release. The enhanced buoyancy and mucoadhesion of the beads 
will be useful for gastroretentive applications. Beads that were both modified with oil and 
coated provided the best combined buoyancy, mucoadhesion and release profile, with the 
beads floating for at least 24 h; over 75 % beads adhering to pig gastric mucosa beyond 8 h 
and ensuring drug release beyond 8 h in gastric pH. The stability of the modified beads was 
also improved in PBS. The coated beads best fitted zero order release kinetics and they 
showed good storage stability at both 4 °C and 20 °C. Therefore, the modification of calcium 
alginate beads with oil and further coating of the beads with chitosan can ensure the 
development of effective sustained release floating-mucoadhesive drug delivery devices and 
provides a potential for a formulation to deliver drugs to the stomach and other parts of the 
GI with higher pH due to its improved stability in alkaline medium. 
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Table 1: CMN loading of unmodified beads, modified beads with olive oil and modified beads 
with olive oil and coating with low molecular weight (LMW) chitosan and high molecular weight (HMW) 
chitosan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Code CMN (w/w) % Olive oil 
(w/w) (%)  
Chitosan 
(w/v) (%) 
E-1 - - - 
E-2 1 - - 
E-3 5 - - 
E-4 10 - - 
E-5 5 10 - 
E-6 10 10 - 
E-7 10 10 0.5 (LMW) 
E-8 10 10 1   (LMW) 
E-9 10 10   0.5 (HMW) 
E-10 10 10 1  (HMW) 
  
Code  % Drug 
loading  
% DEE Diameter 
(mm) 
Bulk 
density 
(g/cm3) 
Porosity 
(%) 
% 
Buoyancy 
Floating lag 
time (min)  
E-1 - -    1.62 (0.4) 0.13 (0.03) 84.98 35 (10) <3  
E-2 22.0 (1.2)    88.0 (4.6) 1.78 (0.2) 0.20 (0.02) 81.29 30 (10) <3 
E-3 53.5 (0.8)    85.5 (1.2) 2.15 (0.1) 0.23 (0.01) 80.97 20 (5) <3 
E-4 66.5 (1.3)    86.5 (1.5) 2.31 (0.3) 0.27 (0.03)        79.91 25 (5) <3 
E-5 24.3 (2.5) 90.0 (9.3)  2.33 (0.4) 0.25 (0.02) 80.68 100 <1 
E-6 40.2 (1.3) 92.5 (3.1) 2.42 (0.2) 0.29 (0.02) 80.44 100 <1 
E-7 35.4 (2.4) 81.2 (5.5) 2.49 (0.3) 0.30 (0.04) 80.19 100 <1 
E-8 37.5 (2.7) 86.3 (6.2) 2.51 (0.4) 0.29 (0.03) 80.74 100 <1 
E-9 36.2 (1.3) 83.3 (2.9) 2.47 (0.2) 0.28 (0.02)  82.34 100 <1 
E-10 40.3 (1.9) 92.7 (4.4) 2.55 (0.3) 0.29 (0.03)  80.78 100 <1 
 
Table 2: Physical characteristics of CMN loaded beads. Results are presented as mean (standard 
deviation) 
 
 
              
                      
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
Table 3: Characteristics of CMN loaded beads. Results are presented as mean (standard deviation) 
 
 
              
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Code Calcium content 
(mg/10mg bead) 
LSC % 
E-1 0.61 (0.08) - 
E-2 0.41 (0.06) 10.71 (2.92) 
E-3 0.32 (0.04) 9.56 (3.18) 
E-4 0.29 (0.04)     8.98(1.73) 
E-5 0.12 (0.02) 5.22(3.74) 
E-6 0.14 (0.02) 6.22(2.18) 
E-7 0.15 (0.02) 1.98(0.42) 
E-8 0.14 (0.01) 2.64(1.52) 
E-9 0.16 (0.03) 2.11(1.92) 
E-10 0.14 (0.01) 2.25(0.73) 
  
 
Code  Zero order First order  Higuchi model Korsmeyer-Peppas 
R2  Ko (h-1) 
 
 
R2 
 
K1(h-1) 
 
R2 
 
Kh (/h-1/2) R2 
 
n 
E2 0.9976 117.12 1.099 0.9965 0.9993 130.4 0.9133 0.41 
E3 0.9841 24.21 0.9791 0.21 0.9937 40.71 0.9829 0.37 
E4 0.9791 20.68 0.9889 0.18 0.9987 38.36 0.9823 0.38 
E6 0.9677 20.69 0.9737 0.16 0.9984 41.19 0.9829 0.45 
E8 0.9969 17.26 0.9229 0.07 0.9914 26.86 0.9796 0.43 
E10 0.9928 15.73 0.9114 0.05 0.9832 24.29 0.9721 0.45 
Table 4:  Dissolution parameters of the beads (pH 2.0) (E2-E4 – unmodified beads); (E6 – oil modified 
beads) and E8 /E10 – chitosan oil modified beads. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                       
        
Fig 1: A) Solubility profile of clarithromycin, B) pH-stability profile of clarithromycin at 37°C; Bar 
presented as mean ± SD (n=3) 
 
B 
A 
        
    
Figure 2: 3D X-ray tomography images of E1 (blank beads) (A&D), E2 (CMN loaded beads) (B & E), E10 
(coated oil-modified beads), (C&F); SEM images of E1 (G) and E10 (H & I). 
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Figure 3: DSC scans of pure CMN, physical mixture of SAL and CMN, CMN loaded beads (E4); oil-
modified beads (E6) and coated oil-modified CMN beads (E10). 
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Figure 4: P-XRD scans of alginate polymer, pure CMN, blank (E1), CMN loaded beads (E4); oil-modified 
beads (E6) and coated oil-modified CMN beads (E10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 5: FTIR scans of pure CMN and blank alginate beads (E1) 
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   Figure 6: FTIR scans of unmodified (E4) beads and coated oil-modified (E10) beads 
 
 
 
 
 
 
    
 
 
 
  
 
     
 
 
Figure 7: Swelling profile of blank (E1), CMN loaded beads (E4); oil-modified beads (E6), 1 % LMW 
chitosan coated oil-modified CMN beads (E8) and 1 % HMW chitosan coated oil-modified CMN beads 
(E10) in A) 0.1 N HCl (pH 2.0) and B) PBS (pH 7.4) 
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  Figure 8: A) Dissolution profiles of pure drug versus drug release from drug loaded beads (E2-E4); 
Comparison of release profiles of CMN loaded beads (E4); oil-modified beads (E6), 1 % LMW chitosan 
coated-oil modified CMN beads (E8) and 1 % HMW chitosan coated oil-modified CMN beads (E10)  in 
B) 0.1N HCl (pH 2.0) and C) PBS (pH 7.4). 
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Figure 9 : Franz cell diffusion studies of the saturated CMN solution, drug loaded beads (E4) and 1 % 
HMW chitosan coated oil-modified CMN beads (E10) in mucin suspension at (A) pH 2 and (B) pH 5.0. 
Results presented as mean ± SD (n=3).  
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Figure 10: A) Zeta potential and B) mucoadhesion of blank (E1), CMN loaded beads (E4); oil-modified 
beads (E6), 1 % LMW chitosan coated oil-modified CMN beads (E8) and 1 % HMW chitosan coated oil-
modified CMN beads (E10) beads determined at pH 2.0 and pH 7.4. 
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